# Medpace Holdings, Inc.  Share Price Target ‘$344.83’, now 8.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/medpace-holdings-inc-share-price-target-344-83-now-8-0-upside-potential/4121188039
- Published: 2025-03-05T12:44:12+00:00
- Author: Charlotte Edwards

**Medpace Holdings, Inc.** with ticker code (MEDP) now have 10 analysts in total
covering the stock. The consensus rating is pointing to ‘buy’. The range between
the high target price and low target price is between $404.00 and $296.00 calculating
the average target share price we see $344.83. (at the time of writing). Now with
the previous closing price of $319.17 this indicates there is a potential upside
of 8.0%. Also worth taking note is the 50 day moving average now sits at $341.93
and the 200 day moving average is $362.44. The company has a market cap of 9.88B.
Currently the stock stands at: $324.39 USD

 The potential market cap would be $10,677,720,772 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 25.7, revenue per share of $68.13
and a 14.86% return on assets.

Medpace Holdings, Inc. is a global provider of clinical research-based drug and 
medical device development services. The Company is focused on providing scientifically
driven outsourced clinical development services to the biotechnology, pharmaceutical
and medical device industries. The Company partners with pharmaceutical, biotechnology,
and medical device companies in the development and execution of clinical trials.
The Company’s drug development services focuses on full-service Phase I-IV clinical
development services and include development plan design, coordinated central laboratory,
project management, regulatory affairs, clinical monitoring, data management and
analysis, pharmacovigilance new drug application submissions, and post-marketing
clinical support. It also provides bio-analytical laboratory services, clinical 
human pharmacology, imaging services, and electrocardiography reading support for
clinical trials. Its operations are based in North America, Europe, and Asia.

Share on:
